Immune responses require a delicate balance: a weak response can cause immunodeficiency, whereas an excessive response can lead to hyperinflammatory disease and hematological malignancy. Because spleen tyrosine kinase has roles in multiple signaling pathways, its gain-of-function alterations in humans cause hypogammaglobulinemia as well as autoinflammation and predisposition to B cell lymphoma.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
LeBien, T. W. & Tedder, T. F. Blood 112, 1570–1580 (2008).
Mócsai, A., Ruland, J. & Tybulewicz, V. L. Nat. Rev. Immunol. 10, 387–402 (2010).
Wang, L. et al.. Nat. Genet. https://doi.org/10.1038/s41588-021-00803-4 (2021).
Turner, M. et al. Nature 378, 298–302 (1995).
Cheng, A. M. et al. Nature 378, 303–306 (1995).
Grammatikos, A. P., Ghosh, D., Devlin, A., Kyttaris, V. C. & Tsokos, G. C. PLoS ONE 8, e74550 (2013).
Csete, D. et al. Front. Immunol. 10, 937 (2019).
Tao, L. & Reese, T. A. Trends Immunol 38, 181–193 (2017).
De Roos, A. J. et al. Cancer Res. 72, 4733–4743 (2012).
Krisenko, M. O. & Geahlen, R. L. Biochim. Biophys. Acta 1853, 254–263 (2015).
Chen, L. et al. Cancer Cell 23, 826–838 (2013).
Herishanu, Y. et al. Blood 117, 563–574 (2011).
Genovese, M. C. et al. J. Rheumatol. 41, 4120–4128 (2014).
Newland, A. & McDonald, V. Immunotherapy 12, 1325–1340 (2020).
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Aksentijevich, I. The sickening consequences of too much SYK signaling. Nat Genet 53, 432–434 (2021). https://doi.org/10.1038/s41588-021-00837-8
This article is cited by
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
Clinical Pharmacokinetics (2022)